> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Shelf Life Evaluation for Bamlanivimab and Etesevimab
- URL: https://www.fdaweb.com/shelf-life-evaluation-for-bamlanivimab-and-etesevimab/
- Published: 2022-04-15T12:00:00.000Z
- Updated: 2026-09-14T17:40:53.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5151614

FDA and HHS have issued a [statement](https://aspr.hhs.gov/COVID-19/Therapeutics/updates/Pages/important-update-13April2022.aspx?utm%5Fcampaign=campaign&utm%5Fmedium=email&utm%5Fsource=govdelivery) that the shelf-life of Eli Lilly’s bamlanivimab and etesevimab, for treating Covid-19, are being evaluated, and an update regarding a shelf-life extension is planned for early next month. In the interim, all bamlanivimab and etesevimab vials may be retained until the shelf-life extension evaluation is complete and posted, regardless of the current labeled expiry date or previously provided extension dates, they say. The recommendation applies to all unopened vials of bamlanivimab and etesevimab that have been held in accordance with refrigerated storage conditions.